Janssen Pharmaceutica NV has divulged mucosa associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer.

Genescience Pharmaceuticals Co. Ltd. has synthesized cellular tumor antigen p53 (TP53) (Y220C mutant) reactivators reported to be useful for the treatment of cancer.

Hangzhou Bio-Creativity Pharma-Tech Co. Ltd. has disclosed phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitors reported to be useful for the treatment of atopic dermatitis.

Ohio State University has described NADH-ubiquinone oxidoreductase (complex I) inhibitors acting as radiosensitizers for radiation therapy reported to be useful for the treatment of cancer.

Forschungsverbund Berlin eV has divulged phosphatidylinositol 4-phosphate 3-kinase (PI3K) inhibitors, particularly PI3K C2 domain-containing subunit β (PIK3C2B) inhibitors, reported to be useful for the treatment of cancer, diabetes, X-linked myotubular myopathy and cardiovascular disorders.

Shanghaitech University has identified thiazolidinedione compounds acting as DNA methyltransferase 3A (DNMT3A) inhibitors reported to be useful for the treatment of acute myeloid leukemia and overgrowth syndrome.

Hangzhou Healthytide Biotechnology Co. Ltd. has synthesized peptoid compounds targeting integrin α5β1 and/or integrin αvβ5 and/or αvβ6 reported to be useful for the diagnosis and treatment of cancer.

Celmatix Inc. has disclosed FSH receptor (FSHR) agonists reported to be useful for the treatment of infertility.

Regor Pharmaceuticals Inc. has divulged phosphatidylinositol 3-kinase (PI3K) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi, skeletal abnormalities and scoliosis, among others.

CVI Pharmaceuticals Ltd. has identified thyroid hormone receptor (THR)-β agonists reported to be useful for the treatment of atherosclerosis, hypercholesterolemia, hyperlipidemia, hepatic steatosis, thyroid cancer, obesity and hypothyroidism.